Hot flash and night sweat reduction
A 12-week double-blind RCT demonstrated EstroG-100® significantly reduced hot flash frequency and severity, night sweat episodes, and overall vasomotor symptom scores compared to placebo. The effect size was clinically meaningful — comparable to low-dose hormone therapy outcomes — without any estrogenic mechanism.
Sleep quality improvement
EstroG-100® significantly improves sleep quality, reduces nighttime waking, and improves sleep duration in menopausal women. The sleep benefits are attributed to both reduction in night sweats (a primary cause of sleep disruption in menopause) and direct effects on neurotransmitter pathways governing sleep architecture.
Vaginal dryness and urogenital symptom relief
Clinical studies confirm EstroG-100® reduces vaginal dryness, urogenital discomfort, and related quality-of-life impairments in menopausal women. These improvements occur through non-estrogenic mechanisms — an important distinction from estrogen-based therapies that carry vaginal tissue estrogenization risks.
Mood, anxiety, and cognitive symptom improvement
EstroG-100® significantly reduces menopausal mood disturbances including irritability, anxiety, and depression, as well as cognitive symptoms like memory lapses and concentration difficulties. The three-herb combination addresses neurotransmitter balance through serotonergic and dopaminergic pathways.
Safe for estrogen-sensitive conditions
The most clinically important differentiator of EstroG-100®: multiple safety studies confirm it does not stimulate estrogen receptors (ERα or ERβ), does not increase breast cancer cell proliferation (MCF-7 assay negative), and does not increase endometrial thickness. Published clinical data in breast cancer survivors on tamoxifen confirms safety and efficacy without interference with cancer treatment.
Non-estrogenic neurotransmitter modulation
EstroG-100® bioactives from the three-herb combination modulate serotonergic (5-HT2A) and dopaminergic (D2) receptors in the hypothalamus — the brain region governing thermoregulation, mood, and sleep. By stabilizing hypothalamic neurotransmitter activity without engaging estrogen receptors, EstroG-100® addresses the neurological root of menopausal symptoms through a fundamentally different pathway than phytoestrogens or HRT.
HPA axis normalization and cortisol modulation
The adaptogenic herb components — particularly Cynanchum wilfordii — normalize hypothalamic-pituitary-adrenal (HPA) axis activity, reducing the cortisol dysregulation that accompanies perimenopause and amplifies hot flashes, sleep disruption, and mood instability. This stress-axis normalization is distinct from estrogen receptor-based mechanisms.
Collagen and mucosal tissue support
Angelica gigas constituents (decursin, decursinol angelate) support collagen synthesis and mucosal tissue integrity through mechanisms independent of estrogen signaling — contributing to improvements in vaginal dryness and skin health observed in clinical trials without the estrogenization risks of topical estrogen therapy.
Randomized, double-blind, placebo-controlled trial of EstroG-100® (514 mg/day) vs. placebo in 64 menopausal women for 12 weeks measuring menopausal symptom index (MRS scale).
64 menopausal women with moderate-to-severe menopausal symptoms. 12-week intervention.
EstroG-100® produced significant improvements across all MRS subscales — vasomotor (hot flashes, night sweats), psychological (mood, anxiety, depression), and urogenital (vaginal dryness, sexual function) symptoms vs. placebo. No estrogenic side effects. Estradiol levels unchanged. Endometrial thickness unchanged. Well-tolerated.
Open-label safety study examining EstroG-100® supplementation in breast cancer survivors on tamoxifen therapy for 12 weeks.
Breast cancer survivors on tamoxifen experiencing menopausal symptoms from hormone suppression therapy.
EstroG-100® significantly reduced menopausal symptom severity without affecting tamoxifen pharmacokinetics, estradiol levels, or breast cancer recurrence risk markers. MCF-7 cell proliferation assay confirmed absence of estrogenic stimulation. Supports EstroG-100® as safe menopausal symptom management for breast cancer survivors where phytoestrogens are contraindicated.
Extended 24-week double-blind RCT examining sustained efficacy and safety of EstroG-100® in menopausal women.
Menopausal women. 24-week double-blind extension study.
Benefits observed at 12 weeks maintained and expanded at 24 weeks. Sleep quality, vasomotor symptom scores, and quality of life continued to improve with sustained use. No tolerance development. No changes in reproductive hormone levels confirming non-estrogenic mechanism. Long-term safety confirmed.